Tesaro (TSRO) PT Raised to $139 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to Tesaro (TSRO) PT Raised to $139 at Wedbush
October 10, 2016 7:51 AM EDT
Baird analyst Michael Ulz reiterated an Outperform rating and raised his price target on Tesaro (NASDAQ: TSRO) to $120.00 (from $105.00) with full niraparib data better than expected.
Ulz commented, "Over the weekend, detailed data from the Phase 3 NOVA study of niraparib in 2L+... More
October 10, 2016 7:27 AM EDT
RBC Capital analyst Adnan Butt reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $128.00 (from $122.00) following NOVA Phase 3 trial details.
Butt commented, "Details show biomarker/HRD-positive benefit is not driven by somatic BRCA patients alone, biomarker/HRD-negative... More
October 10, 2016 7:25 AM EDT
Credit Suisse analyst Alethia Young reiterated an Outperform rating and boosted her price target on Tesaro (NASDAQ: TSRO) to $122.00 (from $90.00) saying the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. They also think the robustness of this data bodes well from... More
October 10, 2016 6:40 AM EDT
Over the weekend, TESARO, Inc. (NASDAQ: TSRO) and ENGOT, the European Network for Gynaecological Oncological Trial groups, today announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress, the congress of the European Society for Medical Oncology (ESMO), by Dr. Mansoor Raza Mirza, M.D., Medical Director of the Nordic Society of Gynecologic Oncology (NSGO) and principal investigator on the ENGOT-OV16/NOVA trial. These data were discussed during the ESMO press briefing in Copenhagen as part of the congress, and were simultaneously published online in the New... More
October 10, 2016 6:34 AM EDT
Leerink Partners analyst Seamus Fernandez reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $115.00 (from $108.00) after full results of the Ph 3 NOVA trial (niraparib as 2L maintenance for ovarian cancer) presented in a Presidential Session at ESMO and... More
